Phase I study of ATN-224 in patients (pts) with advanced solid tumours.
Lowndes SA. et al, (2006), J Clin Oncol, 24
The differential expression of LCK and BAFF-receptor and their role in apoptosis in human lymphomas.
Paterson JC. et al, (2006), Haematologica, 91, 772 - 780
Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors.
Ranson M. et al, (2006), Clin Cancer Res, 12, 1577 - 1584
A case for measuring apoprotein B
Psaila B. and Betteridge DJ., (2006), Case Studies in Lipid Management, 109 - 112
From bone marrow niche to pre-metastatic niche
Kaplan R. et al, (2006), CANCER TREATMENT REVIEWS, 32, S17 - S17
Investigation of the safety, tolerability and pharmacokinetics of Prolarix (TM), which comprises the prodrug tretazicar and a novel synthetic cosubstrate, caricotamide, in patients with late stage cancers
Waterman SC. et al, (2006), ANNALS OF ONCOLOGY, 17, 49 - 49
Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche.
Psaila B. et al, (2006), Breast Dis, 26, 65 - 74
Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide.
Plummer R. et al, (2005), CLINICAL CANCER RESEARCH, 11, 9099S - 9099S
Epoetin alfa: basic biology and clinical utility in cancer patients.
Littlewood T. and Collins G., (2005), Expert Rev Anticancer Ther, 5, 947 - 956
The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer.
Madhusudan S. and Middleton MR., (2005), Cancer Treat Rev, 31, 603 - 617
The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population.
Illing RO. et al, (2005), Br J Cancer, 93, 890 - 895
Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.
Donskov F. et al, (2005), Br J Cancer, 93, 757 - 762
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
Plummer R. et al, (2005), J Clin Oncol, 23
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
Plummer R. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 208S - 208S
Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV).
Midgley R. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 213S - 213S
The use of pharmacokinetic and pharmacodynamic endpoints to determine dose of AQ4N given with radiotherapy (RT).
Benghiat A. et al, (2005), J Clin Oncol, 23
The use of pharmacokinetic and pharmacodynamic endpoints to determine dose of AQ4N given with radiotherapy (RT).
Benghiat A. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 150S - 150S
Drugging cell cycle kinases in cancer therapy.
Blagden S. and de Bono J., (2005), Curr Drug Targets, 6, 325 - 335